MSN
EMERSON RADIO CORP$0.3160 −0.00 (−1.25%)
Oct 27 4:00 PM ET · prev $0.3200
Market cap
$6.9M
Nano cap
Next earnings
Nov 12
in 16 days
1 year
−39.2%
from $0.5200 · Oct 28
30 days
−22.9%
from $0.4100
52-week range
$0.3160–0.5300
at the low
Avg volume 20D
141.5K
shares / day
Short interest
64.2K
≈0.3% of shares · −40.4%
Days to cover
1.0
at average volume
New fund stakes
0
Q1 2026 13F · 0 exits
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- X Sep 15 Short interest jumps 29.4% to 126.9K
- X Oct 15 Short interest falls 40.4% to 64.2K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q1 2026: 1 added (0 new), 0 trimmed or exited.
- Short sellersCOVERING
Short interest −40.4% to 64.2K shares. 1.0 days to cover, ≈0.3% of shares.
- TrendDOWNTREND
25% below its 50-day average. New closing low $0.3160 on Oct 27.
Who's buying
13F· Q1 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $23.5K |
| VANGUARD GROUP INC | TRIM | $12.4K |
| CITIGROUP INC | DOUBLED | $4.1K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $22.9K |
| ROYAL BANK OF CANADA | DOUBLED | $1.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 12, 2026 Earnings calendar
MSN Q1 2027 Earnings Scheduled — 2026-08-12
Mar 31, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
62,324 shares ($23.5K)
Mar 3, 2026 Event
METFORMIN HYDROCHLORIDE
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted i
Dec 31, 2025 Inst.
VANGUARD GROUP INC — TRIM
32,593 shares ($12.4K)
Earnings setup
EstimatesNov 12
reports in 16 days
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 202664,213
shares short
-40.4%
vs prior settlement
1.0
days to cover
≈0.3%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Aug 12, 2026
Earnings date
MSN Q1 2027 Earnings Scheduled — 2026-08-12
Jun 25, 2026
Earnings date
MSN Q4 2026 Earnings Scheduled — 2026-06-25
Mar 18, 2026
Clinical Trial
Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Phase 3 · COMPLETED
Mar 3, 2026
FDA
METFORMIN HYDROCHLORIDE
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant b
Feb 25, 2026
FDA
Clopidogrel
WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE The effectiveness of clopidogrel bisulfate r